Spots Global Cancer Trial Database for Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC

Official Title: CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable Local Advanced Stage III NSCLC

Study ID: NCT03884192

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

Consolidation Sintilimab

Study Description

Brief Summary: This is an open label, multi-center, randomized, control phase III trial, to compare the efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported care (BSC), in unresectable stage III NSCLC patients who do not experience disease progression after initial concurrent chemoradiation.

Detailed Description: This is an open label, multi-center, randomized, control study of sintilimab versus BSC in unresectable local advanced stage III NSCLC patients without disease progression after concurrent chemoradiation.